A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
← catalyst calendarNCT05768269 · readout ≤ 4,973 d
Sponsored by Century Therapeutics, Inc. (industry) · IPSC — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
375estimated
Sites
7
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-29 | actual | When the study began enrolling |
| Primary completion | Mar 2040 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2040 | estimated | The whole study's end, after follow-up |
| First posted | 2023-03-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hematological Malignancy
- Solid Tumor Malignancy
Intervention
- Other: No Intervention
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With any Adverse Events of Special Interest (AESI)
measured Up to 180 months
Permalink · IPSC's whole pipeline · Catalyst calendar · Every registered study · What changed